CoChat

Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial

Open access
Schoultz, Mariyana, Atherton, Iain, Watson, Angus · 2015 · Trials
Cited by 86

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition with a relapsing disease course. Managing the relapsing nature of the disease causes daily stress for IBD patients; thus, IBD patients report higher rates of depression and anxiety than the general population. Mindfulness-based Cognitive Therapy (MBCT) is an evidence-based psychological program designed to help manage depressive and stress symptoms. There has been no randomized controlled trial (RCT) testing the use of MBCT in IBD patients. The purpose of this pilot study is to test the trial methodology and assess the feasibility of conducting a large RCT testing the effectiveness of MBCT in IBD. METHODS: The IBD patients, who were recruited from gastroenterology outpatient clinics at two Scottish NHS Boards, were randomly allocated to an MBCT intervention group (n = 22) or a wait-list control group (n = 22). The MBCT intervention consisted of 16 hours of structured group training over 8 consecutive weeks plus guided home practice and follow-up sessions. The wait-list group received a leaflet entitled 'Staying well with IBD'. All participants completed a baseline, post-intervention and 6-month follow up assessment. The key objectives were to assess patient eligibility and recruitment/dropout rate, to calculate initial estimates of parameters to the proposed outcome measures (depression, anxiety, disease activity, dispositional mindfulness and quality of life) and to estimate sample size for a future large RCT. RESULTS: In total, 350 patients were assessed for eligibility. Of these, 44 eligible patients consented to participate. The recruitment rate was 15%, with main reasons for ineligibility indicated as follows: non-response to invitation, active disease symptoms, planned surgery or incompatibility with group schedule. There was a higher than expected dropout rate of 44%. Initial estimates of parameters to the proposed outcomes at post-intervention and follow-up showed a significant improvement of scores in the MBCT group when compared to the control for depression, trait anxiety and dispositional mindfulness. The sample-size calculation was guided by estimates of clinically important effects in depression scores. CONCLUSIONS: This pilot study suggests that a multicentre randomized clinical trial testing the effectiveness of MBCT for IBD patients is feasible with some changes to the protocol. Improvement in depression, trait anxiety and dispositional mindfulness scores are promising when coupled with patients reporting a perceived improvement of their quality of life. TRIAL REGISTRATION: ISRCTN27934462. 2 August 2013.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-015-0909-5

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 48

  1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590–605. · DOI · Paper page
  2. Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1–16. · DOI · Paper page
  3. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53. · DOI · Paper page
  4. Faust AH, Halpern LF, Danoff-Burg S, Cross RK. Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life. Gastroenterol Hepatol. 2012;8:173.
  5. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389–96. · DOI · Paper page
  6. Keighly MRBSR. Inflammatory bowel disease. Aliment Pharm Ther. 2003;18 suppl 3:66–70. · DOI
  7. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health. 2006;2:24. · DOI
  8. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. It doesn’t do any harm, but patients feel better”: a qualitative exploratory study on gastroenterologists’ perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterol. 2007;7:38. · DOI · Paper page
  9. Goodhand J, Greig F, Koodun Y, McDermott A, Wahed M, Langmead L, et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case‐matched observational study. Inflamm Bowel Dis. 2012;18:1232–9. · DOI · Paper page
  10. Bernal I, Domènech E, Garcia-Planella E, Marín L, Mañosa M, Navarro M, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:2165–9. · DOI
  11. Jackson C, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525–39. · DOI · Paper page
  12. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10:2463–75. · DOI · Paper page
  13. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–8. · DOI · Paper page
  14. Makins R, Ballinger A. Gastrointestinal side effects of drugs. Expert Opin Drug Saf. 2003;2:421–9. · doi:10.1517/14740338.2.4.421
  15. Goodhand JR, Wahed M, Rampton DS. Management of stress in inflammatory bowel disease: a therapeutic option? Expert Rev Gastroenterol Hepatol. 2009;3:661–79. · DOI · Paper page
  16. von Wietersheim J, Kessler H. Psychotherapy with chronic inflammatory bowel disease patients: a review. Inflamm Bowel Dis. 2006;12:1175–84. · DOI · Paper page
  17. Merkes M. Mindfulness-based stress reduction for people with chronic diseases. Aust J Prim Health. 2010;16:200–10. · DOI · Paper page
  18. National Institute for CE. Depression: the treatment and management of depression in adults (update). Leicester: British Psychological Society; 2010.
  19. Jedel S, Merriman P, Hoffman A, Swanson B, Fogg LF, Keshavarzian A. Relationship of mindfulness, quality of life, and psychiatric symptoms among patients with ulcerative colitis. Mindfulness. 2013;4:296–300. · DOI
  20. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. · DOI · Paper page
  21. Schoultz M, Atherton IM, Hubbard G, Watson AJ. The use of mindfulness-based cognitive therapy for improving quality of life for inflammatory bowel disease patients: study protocol for a pilot randomised controlled trial with embedded process evaluation. Trials. 2013;14:431. doi: 10.1186/1745-6215-14-431 . · DOI
  22. Gooberman‐Hill R, Burston A, Clark E, Johnson E, Nolan S, Wells V, et al. Involving Patients in Research: Considering Good Practice. Musculoskelet Care. 2013;11:187–90. · DOI
  23. Williams M, Penman D. Mindfulness: An eight-week plan for finding peace in a frantic world: Rodale. 2011.
  24. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10:1. doi: 10.1186/1471-2288-10-1 . · DOI · Paper page
  25. Cook DJ, Rocker G, Meade M, Guyatt G, Geerts W, Anderson D, et al. Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care. 2005;20:364–72. · DOI
  26. Choi PT, Beattie WS, Bryson GL, Paul JE, Yang H. Effects of neuraxial blockade may be difficult to study using large randomized controlled trials: the PeriOperative Epidural Trial (POET) Pilot Study. PloS One. 2009;4:e4644. · DOI
  27. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18-7015-8-18. · DOI · Paper page
  28. Burgess D, Gebski V, Keech A. EBM: trials on trial. Med J Aust. 2003;179:105–7. · DOI
  29. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77–100. · DOI · Paper page
  30. Akbar A, Yiangou Y, Facer P, Brydon WG, Walters JR, Anand P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010;59:767–74. · DOI · Paper page
  31. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press; 1983.
  32. MacKillop J, Anderson EJ. Further psychometric validation of the mindful attention awareness scale (MAAS). J Psychopathol Behav Assess. 2007;29:289–93. · DOI · Paper page
  33. Goebell H, Wienbeck M, Schomerus H, Malchow H. Evaluation of the Crohn's Disease Activity Index (CDAI) and the Dutch Index for severity and activity of Crohn's disease. An analysis of the data from the European Cooperative Crohn's Disease Study. Med Klin (Munich). 1990;85:573–6.
  34. Sipponen T, Savilahti E, Kolho K, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–6. · DOI · Paper page
  35. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. Gastroenterology. 1976;70:439–44. · DOI · Paper page
  36. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979;77(4 Pt 2):843–6. · DOI · Paper page
  37. Satsangi J. Inflammatory bowel diseases. ed. Jack Satsangi, Lloyd R. Sutherland. Edinburgh: Churchill Livingstone; 2003.
  38. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804–10. · DOI · Paper page
  39. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. Proceedings of the Celebrating Health Research: The Annual R & D Conference. Manchester: North West Regional Health Authority; 2002.
  40. Brouwer D, Meijer RR, Zevalkink J. Measuring individual significant change on the Beck Depression Inventory-II through IRT-based statistics. Psychother Res. 2013;23:489–501. · DOI
  41. Bentley CL, Mountain GA, Thompson J, Fitzsimmons DA, Lowrie K, Parker SG, et al. A pilot randomised controlled trial of a Telehealth intervention in patients with chronic obstructive pulmonary disease: challenges of clinician-led data collection. Trials. 2014;15:313. doi: 10.1186/1745-6215-15-313 . · DOI
  42. Bird L, Arthur A, Cox K. Did the trial kill the intervention?” experiences from the development, implementation and evaluation of a complex intervention. BMC Med Res Methodol. 2011;11:24. · DOI
  43. Roos J, Werbart A. Therapist and relationship factors influencing dropout from individual psychotherapy: A literature review. Psychother Res. 2013;23:394–418. · DOI · Paper page
  44. Robertson DA, Ray J, Diamond I, Edwards JG. Personality profile and affective state of patients with inflammatory bowel disease. Gut. 1989;30:623–6. · DOI · Paper page
  45. Prasko J, Jelenova D, Mihal V. Psychological aspects and psychotherapy of inflammatory bowel diseases and irritable bowel syndrome in children. Biomedical Papers. 2010;154:307–14. · DOI · Paper page
  46. Moreno-Jiménez B, Blanco BL, Rodríguez-Muñoz A, Hernández EG. The influence of personality factors on health-related quality of life of patients with inflammatory bowel disease. J Psychosom Res. 2007;62:39–46. · DOI · Paper page
  47. Boye B, Lundin KE, Leganger S, Mokleby K, Jantschek G, Jantschek I, et al. The INSPIRE study: do personality traits predict general quality of life (short form-36) in distressed patients with ulcerative colitis and Crohn's disease? Scand J Gastroenterol. 2008;43:1505–13. · DOI · Paper page
  48. Bishop S, Forster S. Trait anxiety, neuroticism and the brain basis of vulnerability to affective disorder. In: The Cambridge handbook of human affective neuroscience. Cambridge University Press; 2013. p. 553–74. · DOI

Cited by

See all 86

Metadata

Authors
Schoultz, M., Atherton, I., & Watson, A.
Venue
Trials
Published
2015-08-25
Volume
16
Issue
1
Pages
379-379
ISSN
1745-6215 (ISSN-L)
OpenAlex
W1796426749
Cited by
86
References
33
FWCI
8.92
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial. https://app.cochat.ai/papers/10.1186/s13063-015-0909-5
The paper
Schoultz, M., Atherton, I., & Watson, A. (2015). Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial. Trials. https://doi.org/10.1186/s13063-015-0909-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.